| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Kayyem Jon Faiz | 7.9% | $13,765,571 | 1,149,046 | Jon Faiz Kayyem | 03 Jun 2024 | |||
| Lappe Mark | 6.4% | $11,086,448 | 925,413 | Mark Lappe | 12 Sep 2024 | |||
| BlackRock, Inc. | 4.7% | -17% | $22,917,652 | -$5,101,102 | 680,368 | -18% | BlackRock, Inc. | 30 Sep 2025 |
As of 30 Sep 2025, 101 institutional investors reported holding 10,497,334 shares of Inhibrx Biosciences, Inc. - Common Stock (INBX). This represents 73% of the company’s total 14,475,915 outstanding shares.
The largest institutional shareholders of Inhibrx Biosciences, Inc. - Common Stock (INBX) together control 67% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP | 12% | 1,787,705 | 0% | 0.16% | $60,209,904 |
| PERCEPTIVE ADVISORS LLC | 9.2% | 1,327,707 | +36% | 1.3% | $44,717,171 |
| Sanofi | 8% | 1,157,926 | 0% | 15% | $38,998,948 |
| HighTower Advisors, LLC | 6% | 871,759 | 0% | 0.03% | $29,360,843 |
| BlackRock, Inc. | 4.7% | 684,746 | -6% | 0% | $23,062,245 |
| VANGUARD GROUP INC | 4.1% | 594,918 | -0.59% | 0% | $20,036,838 |
| MORGAN STANLEY | 3.1% | 442,856 | +1493% | 0% | $14,915,390 |
| Sofinnova Investments, Inc. | 3% | 440,092 | -38% | 0.91% | $14,822,299 |
| Woodline Partners LP | 2.3% | 336,590 | -49% | 0.05% | $11,336,351 |
| MILLENNIUM MANAGEMENT LLC | 2.1% | 297,820 | +8% | 0.01% | $10,030,578 |
| PFM Health Sciences, LP | 1.7% | 239,644 | -1.9% | 0.69% | $8,071,210 |
| Caligan Partners LP | 1.6% | 236,383 | 1.1% | $7,961,379 | |
| GEODE CAPITAL MANAGEMENT, LLC | 1.5% | 221,920 | -1.8% | 0% | $7,476,072 |
| STATE STREET CORP | 1.4% | 203,923 | -0.51% | 0% | $6,868,127 |
| READYSTATE ASSET MANAGEMENT LP | 1.2% | 170,158 | +534% | 0.28% | $5,730,921 |
| KENNEDY CAPITAL MANAGEMENT LLC | 1.1% | 161,909 | -8.7% | 0.12% | $5,453,095 |
| Schonfeld Strategic Advisors LLC | 0.67% | 97,382 | -37% | 0.02% | $3,279,825 |
| NORTHERN TRUST CORP | 0.64% | 92,657 | -5.1% | 0% | $3,120,688 |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.54% | 78,812 | +179% | 0.07% | $2,654,388 |
| JANE STREET GROUP, LLC | 0.43% | 62,941 | +225% | 0% | $2,119,853 |
| CITADEL ADVISORS LLC | 0.4% | 57,194 | 0% | $1,926,294 | |
| SummitTX Capital, L.P. | 0.37% | 54,143 | 0.08% | $1,823,536 | |
| Bank of New York Mellon Corp | 0.35% | 50,125 | -0.7% | 0% | $1,688,210 |
| Groupe la Francaise | 0.33% | 47,334 | -38% | 0.02% | $1,594,209 |
| Slotnik Capital, LLC | 0.29% | 41,401 | -78% | 0.5% | $1,394,386 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 43,058 | $3,400,880 | +$1,572,148 | $79.00 | 9 |
| 2025 Q3 | 10,497,334 | $353,550,847 | +$6,764,063 | $33.68 | 101 |
| 2025 Q2 | 10,435,616 | $148,917,132 | -$5,468,523 | $14.27 | 87 |
| 2025 Q1 | 10,790,279 | $150,950,613 | -$5,227,676 | $13.99 | 92 |
| 2024 Q4 | 11,165,626 | $171,927,470 | +$10,221,839 | $15.40 | 101 |
| 2024 Q3 | 8,897,409 | $139,328,871 | -$10,813,194 | $15.66 | 95 |
| 2024 Q2 | 9,650,613 | $136,747,433 | +$136,582,849 | $14.17 | 86 |